Ambiotis is very proud to have actively participated with OSE Immunotherapeutics to the development of an antibody that targets resolution of inflammation pathways. ChemR23 is a GPCR targeted by Resolvin E1. OSE-230 is an anti-ChemR23 agonist antibody that have been shown to promote efferocytosis (clearance of dead cells by macrophages) and reduce apoptosis of neutrophils; major hallmarks of inflammation resolution. It also triggered resolution in chronic colitis model with beneficial impact on tissue lesions, fibrosis and inflammation-driven tumors. This is a first-in-class drug dealing with pro-resolutive properties.

Check the publication here :“Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation”. 

More information

Contact us

+33 (0)5 62 24 41 57

+33 (0)5 61 25 64 02

Send an e-mail via the form

Canal Biotech 2 - 3 Rue des satellites 31400 Toulouse - France

Receive our news

Recent news

Ambiotis - - Copyright © 2017 - All rights reserved - Legal Notice